Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension

Summary

The primary objective of AC-052-373 was to assess the pharmacokinetic (PK) profile of two dosing regimens of the pediatric formulation of bosentan in children with pulmonary arterial hypertension (PAH) \<12 years of age.

Timeline

Start

2011-03-08

Primary completion

2013-04-03

Completion

2013-08-19

Drugs

Indications